Business
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells to be featured in symposia presentation. Exposure-efficacy data from
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells to be featured in symposia presentation. Exposure-efficacy data from Phase 1b/2a study of efzofitimod support efficacy across multiple clinically relevant endpoints in pulmonary sarcoidosis patients. SAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2023 International Conference, which is scheduled to take place May 19 – 24 in Washington, DC. “Our presence at this year’s ATS is an important opportunity for aTyr to feature the research we have generated that further support efzofitimod as a next generation immunomodulator with the potential to be a transformative, disease modifying therapy for interstitial lung disease (ILD),” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. “We present new data showing that by binding to neuropilin-2, efzofitimod modulates immune responses through myeloid cells. By targeting multiple drivers of inflammation, efzofitimod provides a differentiated approach to resolving chronic inflammation. This major advancement in our mechanistic understanding of efzofitimod, in addition to new data that demonstrate a positive exposure-response for efzofitimod on multiple clinically relevant endpoints from a Phase 1b/2a study in pulmonary sarcoidosis patients, provide further evidence of clinical proof-of-concept.” Details of the presentations appear below. The posters will be available on the aTyr website once presented. Title: Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells Session Title: Breakthroughs in ILD: Translation to the BedsideSession Format: Mini SymposiumPoster Number: 9209Date and Time: Monday, May 22, 2023, at 3:15 p.m.Location: Ballroom C (Level 3), Walter E. Washington Convention Center The poster presents findings that investigate the modulatory functions of efzofitimod on monocytes by evaluating peripheral blood mononuclear cells from pulmonary sarcoidosis patients or healthy donors for surface marker...